#Germany #Berlin #Telix Pharmaceuticals #Illuccix #PSMA-PET

Telix Pharmaceuticals Launches Illuccix® in Germany

Telix Pharmaceuticals Limited recently made headlines as its prostate cancer imaging agent, Illuccix® (housing the preparation kit for gallium-68 gozetotide injection), received marketing authorization from the German Federal Institute for Drugs and Medical Devices (BfArM). This pivotal development allows healthcare professionals across Germany to leverage advanced diagnostic capabilities for detecting prostate cancer, specifically targeting prostate-specific membrane antigen (PSMA)-positive lesions in adult patients.

A Critical Advancement in Cancer Diagnostics

Illuccix® is set to revolutionize prostate cancer diagnosis by providing a powerful tool for several clinical settings, including:

• - Primary staging of high-risk patients prior to curative therapy.
• - Evaluating suspected recurrence in patients with rising prostate-specific antigen (PSA) levels following initial treatment.
• - Identifying candidates with metastatic castration-resistant prostate cancer who could benefit from PSMA-targeted therapy.

This technology represents a significant leap forward, effectively replacing older imaging modalities like bone and CT scans, which have become less reliable. Supported by extensive clinical evidence, including data from the VISION trial, the approval comes at a critical time when the demand for precision diagnostic tools in oncology is on the rise.

Addressing Access Challenges

Despite its efficacy, the uptake of PSMA-PET imaging has been hampered in Germany by tracer shortages and infrastructural limitations, leading to prolonged wait times for patients. The introduction of Illuccix® is anticipated to mitigate such barriers by allowing hospitals and clinics to generate PSMA-PET scans on-site. This local production not only expedites access for patients but also enables physicians to optimize their workflows and devote more time to patient care.

Healthcare professional Professor Ken Herrmann, from the University Hospital Essen, emphasized the transformational nature of PSMA-PET imaging in patient treatment and monitoring. He stated that although significant improvements have been made, the limited availability of imaging options has created delays for patients needing timely diagnoses.

Meeting Growing Demand with an Innovative Solution

Raphaël Ortiz, Chief Executive Officer of Telix International, expressed satisfaction with the broad approval of Illuccix®, which underscores the product's clinical relevance across various stages of prostate cancer management. The flexibility of generator-produced gallium, combined with the growing acceptance of PSMA-PET imaging in Europe, positions Illuccix® favorably amidst the evolving landscape of cancer diagnostics.

Partnership for Success

Telix has partnered with Eckert Ziegler SE for the distribution of Illuccix® within Germany. Dr. Harald Hasselmann, CEO of Eckert Ziegler SE, articulated the importance of their collaboration to ensure that this significant imaging agent is readily available to physicians, enhancing prostate cancer care for patients.

The Importance of Tackling Prostate Cancer

In Germany, prostate cancer stands as the most prevalent cancer among men, with over 65,000 new cases diagnosed each year. The disease is also a leading cause of cancer-related deaths. The timely detection and effective management of prostate cancer are pivotal to improving patient outcomes and survival rates.

Summary

As the healthcare sector continues to advance, technologies like Illuccix® are vital in enhancing patient care and providing healthcare professionals with the tools they need to offer timely and accurate diagnoses. The approval of this imaging agent in Germany is a significant step forward in bolstering the capabilities of prostate cancer diagnostics, promising better outcomes for patients affected by this common yet challenging disease.

For further inquiries about Illuccix® or ordering processes, German healthcare professionals can reach out via email or phone, ensuring ready access to this innovative imaging solution for prostate cancer.